Please login to the form below

Not currently logged in
Email:
Password:

BCMA-targeting therapy

This page shows the latest BCMA-targeting therapy news and features for those working in and with pharma, biotech and healthcare.

Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma. ... Aside from the mixed figures, bluebird is looking forward and focusing on the

Latest news

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    or whose disease has relapsed,” said Stanley Frankel, senior vice president, cellular therapy development, BMS. ... In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for

  • J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

    Both candidates are being studied in multiple myeloma. Johnson and Johnson and Bristol-Myers Squibb/Bluebird bio have both revealed data from their respective BCMA-targeting CAR-T therapies in multiple ... BMS/Bluebird also had their own CAR-T data in

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    GSK2857916 is one of a slew of BCMA-targeting therapies coming through the biopharma industry pipeline, jostling for position with a CAR-T therapy from Celgene and Bluebird Bio called bb2121 ... It is the most advanced BCMA-targeting ADC in development,

  • Europe urged to adapt faster to gene therapy challenges Europe urged to adapt faster to gene therapy challenges

    Meanwhile Bluebird is proposing a similar five-year instalment plan for its 1.57m beta thalassemia therapy Zynteglo. ... The next therapy area which could be transformed by cell therapy is multiple myeloma, where BCMA-targeting CAR-T therapies are in the

  • Bluebird’s myeloma CAR-T safety ‘could support outpatient use’ Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

    Expects to file with the FDA next year. Bluebird Bio and partner Celgene have published data for their BCMA-targeting cell therapy bb2121 for multiple myeloma, reinforcing its position as the ... The two partners will have to move fast to stay ahead of a

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics